Steve Noga, MD of Takeda Oncology discusses the results of the phase 3 TOURMALINE-MM4 clinical trial, evaluating ixazomib as maintenance therapy for multiple myeloma.
The results of this study were recently published for the European Hematology Association Annual Meeting and showed significant improvement in progression-free survival for patients treated with ixazomib who had not received stem cell transplantation compared to those receiving placebo. This corresponds with a 34% reduction in risk of progression or death for multiple myeloma patients receiving ixazomib.
Multiple myeloma is a blood cancer associated with uncontrolled growth of plasma cells. Abnormal plasma cells – also known as myeloma cells – interfere with the production of healthy blood cells in the bone marrow. Myeloma cells also produce inactive clones of abnormal antibodies that may negatively affect the bones and kidneys. Symptoms of multiple myeloma may include: bone pain (particularly in the chest and spine), frequent infections, weakness or numbness in the legs, fatigue, confusion, excessive thirst, and constipation.
To keep up to date on the latest developments in multiple myeloma, sign up for our weekly newsletter.